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further evidence to accumulate, including studies that
it has only recently commissioned.
While we do have concerns about the wisdom of
extending prescribing now, we believe that most nurse
and pharmacist prescribers will act within their areas of
competence. For example, a fully trained specialist res-
piratory nurse might prescribe a short course of oral
corticosteroids for a patient with acute asthma but
would be extremely unlikely to alter the drug treatment
of a patient with diabetes or epilepsy without training
in managing these conditions.
To limit the potential risks from extended prescrib-
ing, health professionals must be trained to prescribe
appropriately and safely in the clinical subjects in
which they are likely to practise. The current schemes
for training nurse and pharmacist prescribers are too
short to fully equip a professional for independent
prescribing practice. It is essential that additional train-
ing, support, and mentorship are available after such
training programmes.
In addition, nurse and pharmacist prescribers must
have access to all the tools they need to help them pre-
scribe safely. One worrying finding from the recent
study on independent nurse prescribing in primary
care was that only 5% of nurses had access to systems
providing computer generated prescriptions and most
were probably missing out on the potential benefits of
computerised alerts for drug interactions and aller-
gies.10 This problem could have been predicted from
the way that nurse prescribing was introduced whereby
the guide for implementation11 expected nurses to
hand-write prescriptions rather than being allowed to
use a clinical computer system. Thorough risk
assessments should be done nationally and locally
before prescribing is extended to new clinical areas.
Also, it will be important to have strong clinical gov-
ernance to help to identify any prescriber, medical or
non-medical, exceeding his or her competency. With
appropriate training, support, and governance in place,
extended prescribing could combine the benefits of
high quality pharmaceutical care with greater conveni-
ence and improved access to treatment for patients.
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European developments in labelling allergenic foods
More still needs to be done
The new European Union directive on foodlabelling, requiring manufacturers of packagedfoods to detail clearly the presence of certain
known allergens, comes into effect later this month.1
This welcome legislation will directly benefit the many
people who experience adverse reactions to foods and
could save lives, given the increasing numbers of
people with IgE-mediated food allergy who may
develop anaphylaxis after even minimal exposure.2 3
Similar initiatives are being pursued in the United
States, Australia, and New Zealand, indicating that the
plight of those who live with the daily threat of allergic
reactions to foods is, in some countries at least, at last
being taken seriously.4–6
Manufacturers of packaged foods containing any
of 12 major allergens (see box) will, as of 25 November
this year, be obliged by the European Union
regulations to label these ingredients. Importantly, this
new legislation removes the previously unhelpful “25%
rule,” which exempted labelling of constituent ingredi-
ents if they amounted to less than 25% of the final
product, thereby resulting in an appreciable risk of
inadvertent exposure to, for example, nuts in
chocolates.7 Even use of the smallest quantities of these
12 ingredients will now require labelling.
Although many manufacturers have already begun
implementing this new requirement, consumers need
to be aware that stocks of products manufactured and
packaged before 25 November may continue to be
sold. It is also important to note that other ingredients
of compound preparations may in some cases be
exempt from labelling if they constitute less than 2% of
the final product. Given that sensitisation may be
increasing to, for example, certain stoned or exotic
fruits such as apples or kiwi fruit used in small quanti-
ties in desserts or jams, this is worrying.8 9
More concerning, however, is the exclusion from
these EU regulations of freshly prepared foods, because
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most severe anaphylactic reactions to food occur when
eating out in restaurants and cafes.10 Vulnerable people
are left with one of two options—either to take the risk of
asking about the ingredients of food and trusting in the
advice of catering staff, many of whom will have not
received any training in the dangers of food allergies, or
to curtail or completely avoid eating out. The European
Union should adopt the same requirements as Australa-
sia, where all food suppliers have to make available to
consumers detailed information on ingredients on the
packaging, or on a display alongside the food, or to the
purchaser on request.6
Furthermore, this EU legislation will do nothing
about the highly frustrating general warning “may
contain traces of nuts.”11 To protect people with food
allergies effectively, production lines for the main aller-
gens should be separated completely from other
production lines in factories and other settings for
processing and packaging food products. In the mean-
time, food suppliers should provide consumers with a
much clearer idea of the likelihood of trace exposure
to nuts and other products.
Policy makers, legislators, and food suppliers need
to appreciate that neither underplaying nor overplay-
ing the risks of exposure to allergenic foods are helpful
for those living with what is often a highly debilitating
lifelong condition. People with food allergies need
accurate, clear, and easily understood information to
make truly informed choices and to live with and con-
trol their condition with a sense of confidence.
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Primary care trusts: do they have a future?
Yes as guardians of public sector commissioning; no as service providers
Primary care trusts (PCTs) are the local statutoryorganisations in the English NHS responsible forimproving public health, providing primary
health care, and commissioning secondary and tertiary
care services for populations of around 250 000 people.
When created in 2002 primary care trusts were intended
to become powerful local purchasing agencies, rooted in
primary care, and well placed to integrate primary
health care, community services, and hospital care.1 In
the international context, one of the most notable
features of primary care trusts has been the continuing
belief by NHS policy makers in England in the value of
integrating the purchasing of health care with the deliv-
ery of primary care.However, over the past year or more
the view that primary care trusts are failing to “punch
their weight” in the health system has gained currency, in
particular in relation to their supposed inability to
achieve strategic change in secondary care.2–4
This has led to renewed interest in strengthening the
commissioning function in the NHS. The assumption is
that there will be fewer primary care trusts and that these
will concentrate on funding and contracting for primary
care, supporting the purchasing of other services led by
practice based commissioners, and divesting themselves
of their provider responsibilities such as community
nursing and health visiting.5 This is driven partly by the
perception of the trusts’ “failure” as commissioners. But
it is arguably driven more so by policy makers’
encouragement of a greater range of providers of
primary care beyond traditional NHS general practice6
and the planned roll out of practice based commission-
ing (a scheme whereby practices are delegated a
purchasing budget for their enrolled population) to all
general practices in England by the end of 2006.5
The recent encouragement of a more plural
primary care market, where patients can choose to
enrol with or use a greater range of providers as well as
conventional general practices, arguably represents the
strongest reason for a change to primary care trusts.
Practice based commissioning challenges their com-
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